These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 24267478)

  • 1. The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.
    Tuskey A; Peura D
    Arthritis Res Ther; 2013; 15 Suppl 3(Suppl 3):S6. PubMed ID: 24267478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HZT-501 (DUEXIS(®); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis.
    Schiff M; Peura D
    Expert Rev Gastroenterol Hepatol; 2012 Feb; 6(1):25-35. PubMed ID: 22149579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fixed-dose combination ibuprofen and famotidine (Duexis).
    Med Lett Drugs Ther; 2011 Oct; 53(1376):85-6. PubMed ID: 22033211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
    Bello AE; Kent JD; Holt RJ
    Phys Sportsmed; 2015 Jul; 43(3):193-9. PubMed ID: 26165391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of NSAID-induced gastroduodenal ulcers.
    Rostom A; Dube C; Wells G; Tugwell P; Welch V; Jolicoeur E; McGowan J
    Cochrane Database Syst Rev; 2002; (4):CD002296. PubMed ID: 12519573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis and treatment of NSAID-induced gastroduodenal disorders.
    La Corte R; Caselli M; Castellino G; Bajocchi G; Trotta F
    Drug Saf; 1999 Jun; 20(6):527-43. PubMed ID: 10392669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of NSAID-induced gastroduodenal ulcers.
    Rostom A; Wells G; Tugwell P; Welch V; Dube C; McGowan J
    Cochrane Database Syst Rev; 2000; (4):CD002296. PubMed ID: 11034748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
    Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
    Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment and prevention of NSAID induced gastroduodenal mucosal damage.
    Agrawal NM; Saggioro A
    J Rheumatol Suppl; 1991 Mar; 28():15-8. PubMed ID: 1674754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs.
    McCarthy DM
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):755-73. PubMed ID: 11566039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approaches to healing and prophylaxis of nonsteroidal anti-inflammatory drug-associated ulcers.
    Yeomans ND
    Am J Med; 2001 Jan; 110(1A):24S-28S. PubMed ID: 11165992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy.
    Deeks ED
    Clin Drug Investig; 2013 Sep; 33(9):689-97. PubMed ID: 23881568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Famotidine to prevent peptic ulcer caused by NSAIDs.
    Graham DY
    N Engl J Med; 1996 Oct; 335(17):1322; author reply 1322-3. PubMed ID: 8992333
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial: single-tablet ibuprofen/double-dose famotidine for reduction of gastric and duodenal ulcers (REDUCE Trials): what can be reduced?
    Chan FK
    Am J Gastroenterol; 2012 Mar; 107(3):387-8. PubMed ID: 22388022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
    Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
    Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does famotidine have similar efficacy to misoprostol in the treatment of non-steroidal anti-inflammatory drug-induced gastropathy?
    Wu CS; Wang SH; Chen PC; Wu VC
    Int J Clin Pract; 1998 Oct; 52(7):472-4. PubMed ID: 10622088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of nonsteroidal anti-inflammatory drug-induced gastroduodenal disease by acid suppression.
    Lad R; Armstrong D
    Can J Gastroenterol; 1999 Mar; 13(2):135-42. PubMed ID: 10203432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
    ;
    Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs.
    Taha AS; Hudson N; Hawkey CJ; Swannell AJ; Trye PN; Cottrell J; Mann SG; Simon TJ; Sturrock RD; Russell RI
    N Engl J Med; 1996 May; 334(22):1435-9. PubMed ID: 8618582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials.
    Koch M; Dezi A; Ferrario F; Capurso I
    Arch Intern Med; 1996 Nov; 156(20):2321-32. PubMed ID: 8911239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.